AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 (NASDAQ:ABCL)

Difference thinking concept.


Investment Overview – AbCellera Stock Sinks As Drug Discoverer Fails To Replicate Early Success

I last covered AbCellera for Seeking Alpha back in March, giving its stock a “sell” rating and outlining a few objections I had to the Vancouver, Canada-based drug discoverer’s

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *